Novartis' Rhapsido Meets Primary Endpoints in Chronic Inducible Urticaria Trial

MT Newswires Live06-12

Novartis (NVS) said Friday that a phase 3 trial evaluating Rhapsido (remibrutinib) met primary endpoints across the three most common chronic inducible urticaria subtypes.

Rhapsido showed higher complete response rates versus placebo across the three subtypes, including 29.3% vs 14% in symptomatic dermographism, 56.3% vs 14.6% in cold urticaria and 29.3% vs 15.8% in cholinergic urticaria, the company said.

The drug demonstrated a favorable safety profile with no observed liver safety concerns, Novartis said.

Rhapsido is under FDA review for the symptomatic dermographism subtype and additional submissions to health authorities globally are expected this year, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment